Treatment of chronic post-viral hepatitis C

Chronic post-viral hepatitis C is a major public health problem with around 71 million people infected worldwide. Until 2011 treatment was based on pegylated dual therapy with a sustained virological response (SVR) rate of between 40% and 80% depending on the genotype albeit with a number of contraindications and adverse effects limiting its prescription. The advent of new direct antiviral agents (DAAs) has brought about a metamorphosis in the management of chronic post-viral hepatitis C with SVR reaching 90-100% and few adverse effects. The aim of our work was to evaluate the efficacy and safety of direct antiviral agents in a cohort of patients with chronic post-viral hepatitis C. This was a descriptive cross-sectional prospective study including all patients followed for chronic post-viral hepatitis C in the Nabeul hepato gastroenterology department and who were included in the national hepatitis C virus eradication program.